Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity: Part 2

European Journal of Medicinal Chemistry

Volumn 44, Issue 11, 2009, Pages 4702-4715

  Herold, Franciszek ^a   Izbicki, Łukasz ^a   Chodkowski, Andrzej ^a   Dawidowski, Maciej ^a   Król, Marek ^a   Kleps, Jerzy ^a   Turło, Jadwiga ^a   Wolska, Irena ^b   Nowak, Gabriel ^c,d   Stachowicz, Katarzyna ^c   Dybała, Małgorzata ^d   Siwek, Agata ^d   Nowak, Mateusz ^c   Pieniazek, Elzbieta ^c   Jarończyk, Małgorzata ^e   Sylte, Ingebrigt ^f   Mazurek, Aleksander P ^e  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e National Medicine Institute   (Poland)

^f UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Antidepressants; Dual 5 HT1A SERT activity; Pyrido 1,2 c pyrimidines

Indexed keywords

2 [4 [4 (1H INDOL 3 YL) PIPERIDIN 1 YL]BUTYL] 4 (4 METHOXYPHENYL) 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 2 [4 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 4 (2 TOLYL) 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 2 [4 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 4 (4 TOLYL) 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 2 [4 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 4 PHENYL 5,6,7,8 TETRAHYDROPYRIDOL[1,2 C]PYRIDIMINE 1,3 DIONE; 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 4 (4 TOLYL) 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 4 PHENYL 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 2 [4 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 4 (4 METHOXYPHENYL) 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 2 [4 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL]4 (2 TOLYL) 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 2 [4 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL]4 (4 TOLYL) 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (2 CHLOROPHENYL) 2 [4 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (2 CHLOROPHENYL) 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (2 FLUOROPHENYL) 2 [4 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (2 FLUOROPHENYL) 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (2 FLUOROPHENYL) 2 [4 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (2 METHOXYPHENYL) 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (4 CHLOROPHENYL) 2 [4 [4 (1H INDOL 3 YL]PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (4 CHLOROPHENYL) 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (4 CHLOROPHENYL) 2 [4 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (4 FLUOROPHENYL) 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (4 FLUOROPHENYL) 2 [4 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 4 (4 METHOXYPHENYL) 2 [4 [4 (2 METHYL 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 5,6,7,8 TETRAHYDROPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PYRIMIDINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY TEMPERATURE; BRAIN CORTEX; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FORCED SWIMMING TEST; IC 50; INDUCED HYPOTHERMIA; LOCOMOTION; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; HYPOTHERMIA; MALE; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; PROTEIN BINDING; PYRIMIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349765532     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.07.007     Document Type: Article

References (51)

1. Feighner J.P. J. Clin. Psychiatry 60 Suppl. 4 (1999) 4-11
2. Briner K., and Dodel R.C. Curr. Pharm. Des. 4 (1998) 291-302
3. Labbate L.A., Grimes J.B., and Arana G.W. Biol. Psychiatry 43 (1998) 904-907
4. Invernizzi R., Belli S., and Samanin R. Brain Res. 584 (1992) 322-324
5. Hervas I., and Artigas F. Eur. J. Pharmacol. 358 (1998) 9-18
6. Blier P., De Montigny C., and Chaput Y. J. Clin. Psychiatry 51 (1990) 14-20
7. Artigas F. Trends Pharm. 14 (1993) 262
8. Gartside S.E., Umbers V., Hajos M., and Sharp T. Br. J. Pharmacol. 115 (1995) 1064-1070
9. Bel N., and Artigas F. Synapse 15 (1993) 243-245
10. Kreiss D.S., and Lucki I. J. Pharmacol. Exp. Ther. 269 (1994) 1268-1279
11. Tome M.B., Isaac M.T., Harte R., and Holland C. Int. Clin. Psychopharmacol. 12 (1997) 81-89
12. Zanardi R., Artigas F., and Franchini L. J. Clin. Psychopharmacol. 17 (1997) 446-450
13. Dawson L.A., Nguyen D.L., Smith D.L., and Schechter L.E. J. Psychopharmacol. 16 (2002) 145-152
14. Artigas F., Romero L., De Montigny C., and Blier P. Trends Neurosci. 19 (1996) 378-383
15. Artigas F., Perez V., and Alvarez E. Arch. Gen. Psychiatry 51 (1994) 248-251
16. Artigas F., Celada P., Laruelle M., and Adell A. Trends Pharmacol. Sci. 22 (2001) 224-228
17. Zhou D., Harrison B.L., Shah U., Andree T.H., Hornby G.A., Scerni R., Schechter L.E., Smith D.L., Sullivan K.M., and Mewshaw R.E. Bioorg. Med. Chem. Lett. 16 (2006) 1338-1341
18. Rocco V.P., Spinazze P.G., Kohn T.J., Honigschmidt N.A., Nelson D.L., Wainscott D.B., Ahmad L.J., Shaw J., Threlkeld P.G., Wong D.T., and Takeuchi K. Bioorg. Med. Chem. Lett. 14 (2004) 2653-2656
19. Spinks D., and Spinks G. Curr. Med. Chem. 9 (2002) 799-810
20. Heinrich T., Böttcher H., Gericke R., Bartoszyk G.D., Anzali S., Seyfried C.A., and Greiner H.E. J. Med. Chem. 47 (2004) 4684-4692
21. F. Herold, A. Chodkowski, Ł. Izbicki, M. Król, J. Kleps, I. Wolska, G. Nowak, K. Stachowicz, M. Dybała, A. Siwek, Eur. J. Med. Chem. 44 (2009) 1710-1717.
22. Heiser J.F., and Wilcox C.S. CNS Drugs 10 (1998) 343-353
23. Herold F., Król M., Kleps J., and Nowak G. Eur. J. Med. Chem. 41 (2006) 125-134
24. Matzen L., van Amsterdam C., Rautenberg W., Greiner H.E., Harting J., Seyfried C.A., and Böttcher H. J. Med. Chem. 43 (2000) 1149-1157
25. Guillaume J., Dumont C., Laurent J., and Nedelec L. Eur. J. Med. Chem. Chim. Ther. 22 (1987) 33-43
26. Macor J.E., Burkhart C.A., Heym J.H., Ives J.L., Lebel L.A., Newman M.E., Nielsen J.A., Ryan K., Schulz D.W., Torgersen L., and Koe K. J. Med. Chem. 33 (1990) 2087-2093
27. Herold F., Wolska I., Helbin E., Król M., and Kleps J. J. Heterocycl. Chem. 26 (1999) 389-396
28. Herold F., Kleps J., Anulewicz-Ostrowska R., and Szcze{ogonek}sna B. J. Heterocycl. Chem. 39 (2002) 773-782
29. Macrae C.F., Edgington P.R., McCabe P., Pidcock E., Shields G.P., Taylor R., Towler M., and van de Streek J. J. Appl. Crystallogr. 39 (2006) 453-457
30. Cheng Y.C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099-3108
31. Porsolt R.D., Berlin A., and Jalfre M. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
32. Nowak M., Kołaczkowski M., Pawłowski M., and Bojarski A.J. J. Med. Chem. 49 (2006) 205-214
33. Abagyan R., Totrov M., and Kuznetsov D.N. J. Comput. Chem. 15 (1994) 488-506
34. Yamashita A., Singh S.K., Kawate T., Jin Y., and Gouaux E. Nature 437 (2005) 215-223
35. Jarończyk M., Chilmończyk Z., Mazurek A.P., Nowak G., Ravna A.W., Kristiansen K., and Sylte I. Bioorg. Med. Chem. 16 (2008) 9283-9294
36. Barker E.L., Moore K.R., Rakhshan F., and Blakely R.D. J. Neurosci. 19 (1999) 4705-4717
37. Goodwin G.M., De Souza R.J., and Green A.R. Neuropsychopharmacology 24 (1985) 1187-1194
38. Martin K.F., and Heal D.L. In: Fozar J.R., and Saxena P.R. (Eds). Serotonin: Molecular Biology, Receptors and Functional Effects (1991), Birkhauser Verlag, Basel 483-490
39. Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., and Flether A. Eur. J. Pharmacol. 281 (1995) 81-88
40. Zhang Y., and Skolnick J. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7594-7599
41. Beuming E., Shi L., Javitch A.J., and Weinstein H. Mol. Pharmacol. 70 (2006) 1630-1642
42. Neubauer H.A., Hansen C.G., and Wiborg O. Mol. Pharmacol. 69 (2006) 1242-1250
43. Oxford Diffraction Poland, CrysAlisCCD, CCD data collection GUI, version 1.171. 23, 2003.
44. Oxford Diffraction Poland, CrysAlisRED, CCD data reduction GUI, version 1.171.27, 2005.
45. Sheldrick G.M. Acta Crystallogr. A46 (1990) 467-473
46. Sheldrick G.M. SHELXL97: Program for the Refinement of Crystal Structures (1997), University of Göttingen, Germany
47. Freter K., Fuchs V., Barsumian E., and Oliver J.T. Arzneim.-Forsch./Drug Res. 35 (1985) 272-276
48. Middlemiss D.N., and Fozard J.R. Eur. J. Pharmacol. 90 (1983) 150-153
49. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. J. Pharmacol. Exp. Ther. 283 (1997) 1305-1322
50. Evers A., and Klabunde T. J. Med. Chem. 48 (2005) 1088-1097
51. Wang R., Lai L., and Wang S. J. Comput.-Aided Mol. Des. 16 (2002) 11 [X-Score]